- Open Access
Evaluation of anti-IL-6 monoclonal antibody therapy using murine type II collagen-induced arthritis
© Liang et al; licensee BioMed Central Ltd. 2009
- Received: 15 October 2008
- Accepted: 15 April 2009
- Published: 15 April 2009
Interleukin-6 is a multifunctional cytokine that is critical for T/B-cell differentiation and maturation, immunoglobulin secretion, acute-phase protein production, and macrophage/monocyte functions. Extensive research into the biology of IL-6 has implicated IL-6 in the pathophysiology and pathogenesis of RA. An anti-murine IL-6 mAb that neutralizes mouse IL-6 activities was tested in animal model of collagen-induced arthritis. Prophylactic treatment with anti-IL-6 mAb significantly reduced the incidence and severity of arthritis compared to control mAb treated mice. The mitogenic response of B and T cells isolated from the lymph nodes of anti-IL-6 treated mice was significantly reduced compared to cells isolated from control mAb treated mice. The overall histopathology score for paws from the anti-IL-6 treated mice was significantly reduced when compared to paws from mice treated with control mAb, including both inflammatory (synovitis and pannus) and erosive (erosions and architecture) parameters. Reduced loss of cartilage matrix components was also observed in the anti-IL-6 treated mice. Collectively, these data suggest that IL-6 plays a major role in the pathophysiology of rheumatoid arthritis, and thus support the potential benefit of anti-IL-6 mAb treatment in rheumatoid arthritis patients.
- Juvenile Idiopathic Arthritis
- Collagen Induce Arthritis
- Pannus Formation
- Cell Mitogen
Interleukin-6 (IL-6) is a multifunctional cytokine that is critical for B-cell differentiation and maturation, immunoglobulin secretion, cytotoxic T-cell differentiation, acute-phase protein production, bone marrow progenitor stimulation, renal mesangial cell proliferation, and macrophage/monocyte functions . IL-6 mediates its biological activity through binding to a receptor complex consisting of two glycoproteins, gp80 and gp130 . IL-6 binding to gp80 triggers the dimerization of gp130, which results in the activation of gp130-associated Janus kinase 1 (JAK1) and subsequently signal transduction pathways.
Extensive research into the biology of IL-6 has implicated IL-6 in the pathophysiology and pathogenesis of RA . High levels of IL-6 can be detected in the synovial fluid and serum in RA patients. Local expression of IL-6 may in turn stimulate leukocyte recruitment to the joint, promote osteoclast maturation and activation, potentiate aggrecanase activity to increase proteoglycan breakdown, suppress chondrocytes, and stimulate synovial proliferation, eventually culminating in joint damage [2, 3]. It may also be the relevant cytokine responsible for autoimmune features in RA such as autoreactive T and B cell activation, B cell hyper reactivity and hypergammaglobulinemia . Systemically, elevated IL-6 in patients with RA may induce the acute phase proteins, which contributes to the pathophysiology of some of the comorbidities of RA (ie, atherosclerosis and anemia) .
In preclinical models of inflammatory arthritis, deletion of IL-6 genes has resulted in protection from the induction of collagen-induced arthritis or a reduction in the disease parameters . The studies reported here were designed to further elucidate the influence of IL-6 in arthritis, by examining the effects of anti-IL-6 mAb treatment in a murine model of type II collagen induced arthritis (CIA).
Induction and Assessment of Type II Collagen-induced Arthritis
CIA Treatment Regimen
Arthritis Scoring System
Normal appearance and flexion
Erythema and edema
Visible joint distortion
Ankylosis detectable on flexion
Cellular Proliferative Responses to T and B cell mitogens
In order to determine the effect of anti-IL-6 immunotherapy on lymphocyte proliferative responses, lymph node and spleen cells were stimulated with the T cell mitogen concanavalin A (ConA) and the B cell mitogen lipopolysaccharide (LPS). At the end of the study, lymph nodes and spleens were harvested from mice and single cell suspensions prepared by tissue disruption. Cells were washed, assessed for viability in trypan blue, counted and adjusted to a suspension of 2.5 × 106 cells/mL in RPMI medium supplemented with 5% fetal calf serum (FCS). Aliquots (100 μL) were dispensed into the wells of a 96-well tissue culture plate (Costar) and an equal volume of medium containing either 10 μg/mL ConA or 10 μg/mL LPS was added to appropriate wells of the tissue culture plate. Control wells (medium only) were included on the plate. Plates were incubated at 37°C in a 5% C02 atmosphere for 3 days. Cell proliferation was measured by adding 20 μL of 3-(4, 5 dimethylthiazol-2-yl)-2-5 diphenyl tetrazolium bromide (MTT) solution (5 mg/mL; Sigma) to each well and incubating 6 hours at 37°C in a 5% C02. The culture supernatants were replaced with 200 μL of 10% sodium dodecyl sulfate (SDS) solution, and the plates incubated at 37°C overnight. Optical density (OD) of the wells was read at 590 nm using a microplate photospectrometer (Molecular Devices). Stimulation index (SI) for each response was calculated by comparison with background proliferation (medium control). Antigen and mitogen specific responses were expressed as (OD590 [Stimulated Culture] – OD590 [Spontaneous proliferation culture]).
Inflammatory Parameters of Arthritis Scoring System
Synovitis (judged by the thickness of the synovial membrane)
less than 3 cells thick
3 – 5 cells thick
6 – 10 cells thick
10 – 20 cells thick
20 – 30 cells thick
Beyond 30 cells thick
No pannus formation
Clear pannus attachment
Marked pannus attachment
Joint space filled by pannus
Extensive pannus proliferation
No erosions visible
Minor indentation in area of capsular attachment
Clear erosions of cartilage
Erosions extend into subchondral bone
Major erosion of bone and cartilage
Loss of visible cartilage and major bone loss
Normal joint architecture
Minor subluxation of articulating surfaces
Major subluxation of articulating surfaces
Loss of joint landmarks
Complete fibrosis and collagen bridging
Classical normal joint appearance
Minor changes; consistent with remission; may be clinically normal.
Moderate inflammatory disease
Major inflammatory disease
Destructive, erosive arthritis
Destructive, erosive arthritis with major bone remodeling.
Cartilage and Bone Matrix degradation
Matrix Degradation Scoring System
No visible Toluidine Blue staining
Very weak Toluidine Blue staining only in the deep cartilage
Weak Toluidine Blue staining
Moderate Toluidine Blue staining
Some loss of staining from the superficial cartilage
Normal Toluidine Blue staining
No visible Aldehyde Fuchsia staining
Very weak Aldehyde Fuchsia staining only in the deep cartilage
Weak Aldehyde Fuchsia staining
Moderate Aldehyde Fuchsia staining
Some loss of staining from the superficial cartilage
Normal Aldehyde Fuchsia staining
Serum amyloid A (SAA) analysis by enzyme-linked immunosorbent assay (ELISA)
SAA levels were determined by ELISA (Biosource, Camarillo, CA) according to the manufacturer's recommendations. Briefly, serum samples were diluted 1:200 in assay diluent and incubated with conjugated anti-mouse SAA antibody. Following multiple plate wash cycles, the substrate tetramethylbenzidine was added, and the optical density of the samples was read at OD450 nm. The results were analyzed to determine SAA using a four-parameter fit of the standard curve provided to determine sample levels of SAA.
Real-time PCR analysis of Paw RNA
Paws were harvested as described above and tissues homogenized with a Polytron RT 2000 in 7.5 M guanidium-HCl for 3 minutes, followed by the addition of sodium lauryl sarcosinate to a final concentration of 0.5%. After centrifugation to remove debris, and the addition of 2 M potassium acetate and 1 M acetic acid, RNA was precipitated by the addition of cold absolute ethanol. Total RNA was isolated and processed using the RNAzol method (Tel-Test, Friendswood, TX) according to the manufacturers instructions. The quantity and purity of RNA was determined by absorbance on a spectrophotometer (Beckman Instruments, Fullerton, CA.) at 260 nm and 280 nm. Samples with ratios > 1.7 were accepted for analysis. To analyze the gene expression real time reverse-transcription polymerase chain reactions (RT-PCR) were performed and the gene activity of OPG and TNFα examined. cDNA was reverse transcribed from 0.5 μg of total RNA in a 20 μl reaction mixture containing 1× PCR buffer, 500 μM each of deoxynucleotide triphosphates (dNTP), 0.5 U/μl of RNAse inhibitor, 2.5 μM random hexamers, 5.5 mM MgCl2, and 1.25 U/μl of reverse transcriptase (Perkin Elmer, CT). The reaction mixture was incubated in a Thermal Cycler (Perkin Elmer, CT) at 25°C for 10 minutes, 48°C for 25 minutes followed by 95°C for 5 minutes. Real time PCR was performed according to manufacturer's instructions. To standardize target gene level with respect to variability in quality of RNA and cDNA, we used glyceraldehyde-3-phosphate dehydrogenase (GAPDH) transcripts, a housekeeping gene, as an internal control. Reaction mixtures of 25 μl included 12.5-μl of 2× SYBR® Green Master Mix and target gene primer pairs (at 400 nM final concentration) and 2 μl cDNA. The sequences of the primers were purchased from Clontech, CA. All reagents were from Perkin Elmer/Applied Biosystems. The reactions were run in MicroAmp optical 96-well reaction plates with MicroAmp optical caps for 40 cycles (95°C/15-seconds, 60°C/1-min) in the ABI Prism 7700 Sequence Detector (PE-Applied Biosystems, Foster City, CA) and the fluorescent signals were recorded dynamically. Normalization and analysis of the reporter signals (ΔRn) at the threshold cycle was recorded by the machine built-in software, and target gene copies were calculated against the regression of the standard curve.
Appropriate statistical comparisons (Kruskal-Wallis ANOVA and Mann-Whitney U tests) were performed to assess the influence of anti-IL-6 on disease progression (based on cumulative arthritis score) and histological assessment. Appropriate statistical comparisons were also performed to assess the influence of treatment on the cellular immune response with respect to the T cell mitogen ConA and the B cell mitogen LPS. One-way ANOVA tests were performed to assess the influence of IL-6 antibody on histopathological features of disease and loss of cartilage matrix proteins. Post-hoc LSD scores were used to assess differences between the individual groups, and compared both treatment groups to control, and the two treatment groups together. P values < 0.05 were considered statistically significant.
Influence of IL-6 antibody on collagen-induced arthritis
Immunological assessment of proliferative responses of spleen and lymph node cells
Influence of IL-6 antibody on the inflammatory histopathology of CIA
Influence of IL-6 antibody on the erosive histopathology of collagen-induced arthritis
Influence of IL-6 antibody on loss of cartilage matrix components
Influence of IL-6 antibody on serum SAA levels
Influence of anti-IL-6 treatment on TNFα and osteoprotegerin expression in paws
An anti-murine IL-6 mAb that neutralizes mouse IL-6 activities was tested in an animal model of CIA. Prophylactic treatment with anti-IL-6 mAb significantly reduced the incidence and severity of arthritis as compared to control mAb treatment. The overall histopathology score for paws harvested from anti-IL-6 treated mice was significantly reduced when compared to paws harvested from mice treated with control mAb, including both inflammatory (synovitis and pannus) and erosive (erosions and architecture) parameters. A linear dose response relationship was not observed in the study, with a similar efficacy observed between the 5 mg/week and the 1 mg/week doses during the majority of the trial. This suggests that a maximum threshold of anti-arthritic activity may be achieved by anti-IL-6 at or even below the 1 mg/week dose level. Thus the current study cannot provide pharmacokinetics on the efficacy of anti-IL-6 therapy, beyond the observation of a marked reduction in disease parameters. The mitogenic response of B and T cells isolated from the lymph nodes of anti-IL-6 treated mice was significantly reduced compared to cells isolated from control mAb treated mice. These data suggest that IL-6 plays a major role in the pathophysiology of rheumatoid arthritis, and thus indicate that anti-IL-6 mAb may be beneficial in the therapy for RA patients.
IL-6 mediates both acute and chronic phases of inflammatory responses, therefore involved in early and late stages of inflammation. IL-6 plays a critical role in stimulating T/B cell proliferation and differentiation. Circulating serum IL-6 has been shown to be elevated in multiple inflammatory diseases including RA, systemic juvenile idiopathic arthritis, systemic lupus erythematosus, ankylosing spondylitis, psoriasis and Crohn's disease . A clear correlation between IL-6 levels and markers of inflammation was established in patients with these diseases. IL-6-mediated chronic inflammatory proliferation results in the typical plasmacytosis and hyperplasia of synovial cells in the joints of rheumatoid arthritis patients as well as in control animals in our study. IL-6 dose not only initiate and maintain inflammation, but also perpetuate inflammatory responses through manipulation of the various cell types involved in inflammation. Our current study demonstrated that anti-IL-6 mAb treatment effectively suppressed IL-6 bioactivities and subsequent disease development in a murine RA model.
IL-6 has been reported to stimulate endothelial cell production, resulting in the release of IL-8 and monocyte chemoattractant protein, expression of adhesion molecules, and recruitment of leukocytes to inflammatory sites . Furthermore, IL-6 can stimulate synoviocyte proliferation and osteoclast activation, resulting in synovial pannus formation . With the help of IL-1, IL-6 can increase production of matrix metalloproteinases, which ultimately contributes to joint and cartilage destruction . Synovitis and pannus formation were significantly reduced in the anti-IL-6 mAb treated mice as compared to that of the control mAb treated mice in the current study, indicating the efficacy of the anti-IL-6 mAb in suppressing histological degradation in this RA model. IL-6 receptor subunit gp130 transgenic mice that have excess spontaneous IL-6 signaling have been reported to develop a joint disease that is similar to RA which is triggered by lymphocyte activation and accompanied by autoantibody formation . However, deletion of IL-6 gene has resulted in protection from the induction of collagen-induced arthritis or a reduction in the disease parameters . Intra-articular administration of IL-6 into the joints of IL-6-deficient mice did not lead to arthritis, but a soluble IL-6/IL-6R fusion protein caused joint swelling and other symptoms of arthritis . Other animal studies have demonstrated that IL-6 is critical in the development of experimental arthritis. The development of CIA in anti-mouse IL-6R antibody (MR16-1)-treated mice was significantly inhibited . Similar results have also been reported in antigen-induced arthritis in mice  and in SKG mice that spontaneously develop autoimmune arthritis . In summary, these results suggest that reduced levels of IL-6 protect against development of inflammatory arthritis, while excess IL-6 signaling contributes to disease development. Our currently study confirms this finding.
Validation of the IL-6 signaling pathway as a target in RA has also been established by the clinical efficacy in multicenter trials of tocilizumab, a humanized anti-IL-6 receptor antibody , and in a pilot study of B-E8, a murine anti-IL-6 monoclonal antibody (mAb) . Tocilizumab treatment resulted in rapid improvements in arthritis and fever in an open-label study in children with systemic-onset juvenile idiopathic arthritis. Tocilizumab also has demonstrated inhibition of radiographic progression in one trial, further supporting the tenet that blocking the IL-6 pathway interrupts inflammatory disease processes in RA. We believe both of the anti-IL-6 and anti-IL-6R mAbs will block IL-6 signaling and the inflammation mediated by IL-6, however, these two approaches might be different in terms of relevant indications, efficacy, and toxicity profile, especially in chronic diseases.
IL-6 is required for CIA development, and the control of osteoclast formation, activation and apoptosis is mediated in part by OPG, a secreted TNF receptor family member that functions as a decoy receptor for RANKL, inhibiting osteoclast formation and activation, and accelerating apoptosis. Studies have shown that OPG reduces osteoclast numbers and prevents bone erosion in CIA. It has also been shown that decreased levels of IL-6 and increased levels on OPG lead to a protective effect on bone destruction in CIA. In our study, anti-IL-6 mAb treatment decreased TNFa levels and increased OPG levels in paws of mice after induction of CIA. The mechanism of action of IL-6 may have been through a decrease in the activity of TNFa, a potent osteoclastogenic cytokine that is known to be central to the pathogenesis of RA, and an increase in OPG, leading to decreased osteoclast formation and activity.
Taken together, our study confirms the strong link between IL-6 and autoimmune arthritis in an animal model. Biologic blocking IL-6 ligand has led to the amelioration of RA symptoms and disease activities. We believe targeting the ligand might be different from targeting the receptor in terms of efficacy and toxicity as we gradually learn from the other biologic therapeutics such as TNFα and TNFα receptor mAbs. Our study represents an alternative approach to block the IL-6 signaling.
- Kishimoto T: Interleukin-6: from basic science to medicine – 40 years in immunology. Annu Rev Immunol. 2005, 23: 1-21. 10.1146/annurev.immunol.23.021704.115806.PubMedView ArticleGoogle Scholar
- Lipsky PE: Interleukin-6 and rheumatic diseases. Arthritis Research & Therapy. 2006, 8 (Suppl 2): S4-8. 10.1186/ar1918.View ArticleGoogle Scholar
- Flannery C, Little C, Hughes C, Curtisa C, Caterson B, Jones S: IL-6 and its soluble receptor augment aggrecanase-mediated proteoglycan catabolism in articular cartilage. MatrixBiology. 2000, 19: 549-553.Google Scholar
- Ishihara K, Hiranoa T: IL-6 inautoimmune disease and chronic inflammatory proliferative disease. Cytokine & Growth Factor Reviews. 2002, 13: 357-368. 10.1016/S1359-6101(02)00027-8.View ArticleGoogle Scholar
- Ohsugi Y: Recent Advances in Immunopathophysiology of Interleukin-6: An Innovative Therapeutic Drug, Tocilizumab (Recombinant Humanized AntihumanInterleukin-6 Receptor Antibody), Unveils The Mysterious Etiology of Immune-Mediated Inflammatory Diseases. Biol Pharm Bull. 2007, 30: 2001-2006. 10.1248/bpb.30.2001.PubMedView ArticleGoogle Scholar
- Park JY, Pillinger MH: Interleukin-6 in the pathogenesis of rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2007, 65 (Suppl 1): S4-10.PubMedGoogle Scholar
- Seideman J, Peritt D: A novel monoclonal antibody screening method using the Luminex-100™ microsphere system. J Immunol Methods. 2002, 267: 165-171. 10.1016/S0022-1759(02)00168-0.PubMedView ArticleGoogle Scholar
- Wooley PH, Luthra HS, Stuart JM, David CS: Type II collagen-induced arthritis in mice. I. Major histocompatibility complex (I region) linkage and antibody correlates. J Exp Med. 1981, 154: 688-700. 10.1084/jem.154.3.688.PubMedView ArticleGoogle Scholar
- Gabay C: Interleukin-6 and chronic inflammation. Arthritis Res Ther. 2006, 8 (suppl 2): S3-10.1186/ar1917.PubMedPubMed CentralView ArticleGoogle Scholar
- Wong PK, Campbell IK, Egan PJ, Ernst M, Wicks IP: The role of the interleukin-6 family of cytokines in inflammatory arthritis and bone turnover. Arthritis Rheumatology. 2003, 48: 1177-89. 10.1002/art.10943.View ArticleGoogle Scholar
- Atsumi T, Ishihara K, Kamimura D, Ikushima H, Ohtani T, Hirota S, Kobayashi H, Park SJ, Saeki Y, Kitamura Y, Hirano T: A point mutation of Tyr-759 in interleukin 6 family cytokine receptor subunit gp130 causes autoimmune arthritis. J Exp Med. 2002, 196: 979-90. 10.1084/jem.20020619.PubMedPubMed CentralView ArticleGoogle Scholar
- Nowell MA, Richards PJ, Horiuchi S, Yamamoto N, Rose-John S, Topley N, Williams AS, Jones SA: Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130. J Immunol. 2003, 171: 3202-9.PubMedView ArticleGoogle Scholar
- Takagi N, Mihara M, Moriya Y, Nishimoto N, Yoshizaki K, Kishimoto T, Takeda Y, Ohsugi Y: Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. Arthritis Rheum. 1998, 41: 2117-21. 10.1002/1529-0131(199812)41:12<2117::AID-ART6>3.0.CO;2-P.PubMedView ArticleGoogle Scholar
- Ohshima S, Saeki Y, Mima T, Sasai M, Nishioka K, Nomura S, Kopf M, Katada Y, Tanaka T, Suemura M, Kishimoto T: Interleukin 6 plays a key role in the development of antigen-induced arthritis. Proc Natl Acad Sci USA. 1998, 95: 8222-6. 10.1073/pnas.95.14.8222.PubMedPubMed CentralView ArticleGoogle Scholar
- Hata H, Sakaguchi N, Yoshitomi H, Iwakura Y, Sekikawa K, Azuma Y, Kanai C, Moriizumi E, Nomura T, Nakamura T, Sakaguchi S: Distinct contribution of IL-6, TNF-alpha, IL-1, and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice. J Clin Invest. 2004, 114: 582-8.PubMedPubMed CentralView ArticleGoogle Scholar
- Kavanaugh A: Interleukin-6 inhibition and clinical efficacy in rheumatoid arthritis treatment: data from randomized clinical trials. Bull NYU Hosp Jt Dis. 2007, 65 (Suppl 1): S16-20.PubMedGoogle Scholar
- Wendling D, Racadot E, Wijdenes J: Treatment of severe rheumatoid arthritis by antiinterleukin6 monoclonal antibody. J Rheumatol. 1993, 20: 259-62.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.